Ticker: HUM

Humana

Healthcare Healthcare Medical - Healthcare Plans

Price 402.96

Reco Buy Potential 67 Risk 36 Updated 2026-09-10

Official website

Forecast impact

positive

Target +12.5% target fill 88.9%

Reaction D5 +0.99% · D10 +6.01% fresh confirmed · market trust

Impact Potential +6 · Risk -3 valid until 2026-09-23

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Humana Inc. is a healthcare company that provides health insurance and related services. Its core products include Medicare Advantage plans, Medicaid services, and individual and group health insurance plans. Major business segments consist of Retail, Group and Specialty, and Healthcare Services. The primary revenue sources are premiums from health insurance policies and government contracts for Medicare and Medicaid services.

Investment Profile

Humana's stock is positioned for balanced investors, offering moderate growth potential alongside a dividend yield. The company's stable revenue growth and consistent earnings performance suggest a reliable investment profile. It may appeal to those seeking a combination of capital appreciation and income generation.

Category: Healthcare Sector: Healthcare Industry: Medical - Healthcare Plans Investment style: Growth Horizon: Medium-term Company type: Blue Chip

Fundamental metrics (experimental) Updated: 2026-09-10

EPS (TTM) — earnings per share for the last 12 months, $: 9.38
Revenue QoQ — quarter-over-quarter revenue growth: 21.9%
EPS surprise: 3.4%
20d volatility: 1.1%
Dividend yield: 1.2%
last ex-date: 2026-06-26

AI recommendation changes

Date	Before	After	Reason
2026-08-04	Hold	Buy	Strong fundamentals, but recent momentum is concerning.
2026-07-26	Buy	Hold	Strong revenue growth, but high risk and negative momentum.
2026-05-24	Hold	Buy	Strong growth and positive momentum support bullish outlook.
2026-05-16	Buy	Hold	Strong momentum and solid earnings growth support bullish outlook.
2026-05-08	—	Buy	Strong fundamentals and positive momentum support growth outlook.
2026-05-05	Hold	Buy	Компания показывает сильный рост выручки и положительную динамику акций за последние 20 и 60 дней. Умеренный риск связан с недавним снижением цены за 120 дней.
2026-04-09	Sell	Hold	Несмотря на недавний рост акций, компания испытывает значительное снижение на более длительных временных интервалах. Учитывая текущие показатели и неопределенность в секторе здравоохранения, рекомендуется удерживать акци
2026-03-23	Hold	Sell	Компания Humana демонстрирует значительное снижение цен за последние два месяца, что указывает на высокие риски. Однако, дивидендная доходность и небольшое превышение ожиданий по прибыли могут поддерживать интерес инвест
2026-03-14	Sell	Hold	Компания Humana демонстрирует значительное снижение цен за последние месяцы, что указывает на высокие риски. Однако стабильная дивидендная доходность и положительный EPS могут поддерживать интерес инвесторов.
2026-01-28	Hold	Sell	Существенное падение акций компании за последние месяцы указывает на высокие риски, а отсутствие данных о прибыли и доходах делает ситуацию еще более неопределенной.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-08-24	Wolfe Research	Target Raised	— → 450	378.87
2026-08-04	Morgan Stanley	Rating Upgraded	— → 370	362.16
2026-07-31	Barclays	Target Raised	344 → 407	366.61
2026-07-30	Piper Sandler	Update	— → 463	369.62
2026-07-30	UBS	Target Raised	320 → 405	367.84
2026-07-30	Oppenheimer	Target Raised	340 → 405	367.16
2026-07-30	Robert W. Baird	Target Raised	205 → 390	365.89
2026-07-30	Guggenheim	Target Raised	269 → 471	365.89
2026-07-30	Leerink Partners	Target Raised	255 → 513	365.89
2026-07-29	Evercore ISI	Rating Upgraded	— → 480	365.45
2026-07-20	Jefferies	Target Raised	— → 410	398.25
2026-07-14	Truist Financial	Target Raised	320 → 415	406
2026-07-13	Wells Fargo	Rating Upgraded	— → 502	392.22
2026-07-09	RBC Capital	Target Raised	246 → 415	401.335
2026-07-07	Cantor Fitzgerald	Target Raised	— → 300	392.86
2026-07-07	Raymond James	Target Raised	264 → 300	392.86
2026-06-08	Mizuho Securities	Target Raised	335 → 390	350.08
2026-06-04	Morgan Stanley	Target Raised	217 → 249	327.54
2026-06-03	Bernstein	Target Raised	288 → 425	320.88
2026-06-01	Truist Financial	Target Raised	270 → 320	305.42
2026-05-26	Barclays	Target Raised	180 → 344	300.86
2026-05-22	UBS	Target Raised	262 → 320	303.68
2026-05-20	Mizuho Securities	Target Raised	290 → 335	310.55
2026-05-20	Deutsche Bank	Rating Upgraded	— → 441	310.55
2026-05-15	Morgan Stanley	Target Raised	146 → 217	301.35
2026-05-13	Piper Sandler	Target Raised	182 → 254	295.35
2026-05-01	Raymond James	Target Raised	230 → 260	236.44
2026-04-30	RBC Capital	Target Raised	189 → 246	240.92
2026-04-30	Deutsche Bank	Target Raised	180 → 235	241.1
2026-04-30	Oppenheimer	Target Raised	250 → 260	242.68

News Page 1 of 1

Thyme Care Secures $125 Million in Series E Funding, Valuation Surpasses $2 Billion

09/02/2026, 08:36 AM economy fundraising Humana CVS Health

Thyme Care has successfully raised $125 million in a Series E funding round, increasing its valuation to over $2 billion, which highlights the growing investor interest in innovative solutions for cancer care management.

Analysts Evercore ISI add Humana (HUM) and NRG Energy (NRG) to their Best Core Ideas list, highlighting dividend potential

08/04/2026, 01:37 PM investing recommendation Analysts: analysts, Evercore ISI healthcare energy NRG Energy Humana

Evercore ISI has updated its Best Core Ideas list, adding dividend-paying stocks Humana and NRG Energy, which are expected to perform well over the next year. This move highlights the firm's focus on stocks with strong fundamentals and potential for growth, particularly in the health insurance and utilities sectors.

Humana (HUM) Reports Strong Q2 Earnings, Maintains 2026 Profit Outlook Amid Stable Medical Costs

07/29/2026, 06:37 AM business review healthcare Humana

Humana's second-quarter earnings exceeded expectations, but the company's unchanged profit outlook disappointed some analysts, leading to a decline in its stock price despite strong performance in its insurance and healthcare services segments.

Analysts Deutsche Bank highlight top investment ideas for Q3 2026, including Oracle (ORCL) and Starbucks (SBUX)

06/30/2026, 09:37 AM investing research Analysts: analysts, Deutsche Bank software consumer Oracle AppLovin Humana American International Group Ralph Lauren Wyndham Hotels & Resorts Starbucks

Deutsche Bank has released its top stock picks for the third quarter, highlighting 41 companies across various sectors that are expected to perform well, including Oracle and Starbucks. This list has historically outperformed the market, making it a valuable resource for investors.

Dow Jones Industrial Average Hits Record High as Health-Care Stocks Lead Market Gains

06/05/2026, 05:34 AM business review healthcare UnitedHealth Humana Centene Eli Lilly

Despite a decline in chip stocks, the U.S. stock market saw significant gains, with the Dow Jones Industrial Average reaching a new record, driven largely by strong performance in the health-care sector.

Stocks Surge and Decline Midday: MGM Resorts, Zoom Communications, Nvidia, and Others Report Significant Movements

06/01/2026, 10:35 AM business review software consumer Zoom Communications Microsoft Nvidia Veeva Systems Dell Technologies Viasat Humana MGM HP

Several companies experienced significant stock movements, driven by acquisition offers, earnings reports, and new product announcements, which could influence investor sentiment and market dynamics.